WuXi Healthcare Ventures

Adlai Nortye Biopharma Co., Ltd. is a clinical-stage biopharmaceutical company specializing in the research and development of innovative cancer therapies and treatments for metabolic diseases. Founded in 2004 and based in Hangzhou, China, the company has established research and development and clinical operations in both China and the United States. Adlai Nortye has a diverse pipeline of over ten drug candidates, including several in various stages of clinical development, such as buparlisib (AN2025), palupiprant (AN0025), and AN4005, alongside preclinical candidates like AN8025, AN9025, and AN1025. The company emphasizes collaborations and internal discoveries to advance its strategic focus on oncology.

Zenas BioPharma is a clinical-stage biopharmaceutical company based in Florida, dedicated to developing immune-based therapies for patients. The company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody that targets both CD19 and FcγRIIb, which are found on B cells. This innovative approach aims to inhibit the activity of B cells involved in various autoimmune diseases while preserving their overall population, thus offering a potential therapeutic advantage over traditional treatments that deplete these cells.

LifeMine Therapeutics, Inc. is a biotechnology company focused on discovering new drug modalities from eukaryotic microbes, particularly fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, the company employs an integrated platform that combines genomics, artificial intelligence, and synthetic biology. This innovative Avatar-Rx platform utilizes high-throughput microbiology, data science, machine learning, genome engineering, and automation to explore the fungal biosphere for novel genetically encoded molecules with specific biological functions. By integrating chemoinformatic-assisted drug optimization and advanced chemical synthesis with biotransformation, LifeMine Therapeutics aims to advance a pipeline of new medicines into development.

XW Laboratories Inc. is a biopharmaceutical company based in Wuhan, China, specializing in the discovery and development of innovative treatments for neurological disorders. Established in 2014, the company has created three distinctive research and development platforms, including Prodrug and Functional Group Switch, which facilitate the rapid identification of new drug candidates while minimizing development costs and time. XW Laboratories aims to enhance patient compliance and reduce toxicity associated with existing medications. In addition to focusing on the domestic market, the company collaborates with international partners to extend its reach in foreign markets, positioning itself at the forefront of medicinal technology in the Asia-Pacific region.

Halda Therapeutics is a research-stage drug discovery company focused on developing next-generation precision medicines. The company utilizes a novel therapeutic modality aimed at creating treatments that can address various disease states. By modifying disease-causing pathways, Halda Therapeutics seeks to enable healthcare providers to offer tailored therapies to patients, enhancing the effectiveness of treatment based on individual patient needs.

Antengene Corporation is a biopharmaceutical company based in Shanghai, China, founded in 2016, that specializes in the development of innovative therapies for cancer treatment. The company's portfolio includes ATG-010 (selinexor), targeting hematologic malignancies such as multiple myeloma, and ATG-008 (onatasertib), an mTOR kinase inhibitor aimed at treating advanced solid tumors and hematological malignancies. Antengene's pipeline features several investigational products, including ATG-016 (eltanexor), ATG-527 (verdinexor), and ATG-019, along with pre-clinical candidates like ATG-101, a bi-specific antibody, and ATG-012, a KRAS G12C inhibitor. The company is committed to addressing unmet medical needs in Asia through its focus on the discovery, development, and commercialization of first-in-class therapeutics for various types of cancer.

Refuge Biotechnologies, Inc. is a Menlo Park, California-based company focused on developing cancer immunotherapies through the application of synthetic biology and gene-editing technology, specifically CRISPR-dCas. Founded in 2015, Refuge aims to enhance cell therapies by creating innovative treatments that can sense their environment and modulate multiple genes simultaneously. This approach allows for more potent and targeted cancer therapies, moving beyond traditional single-target treatments. The company's research and development efforts are centered on advancing both cancer diagnostics and immunotherapies to improve patient outcomes in cancer care.

Unity Biotechnology is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span by addressing diseases associated with aging. The company specializes in clearing senescent cells through the creation of senolytic medicines, which target vulnerabilities specific to these cells while preserving normal ones. Its lead drug candidates include UBX0101, currently undergoing Phase II trials for musculoskeletal disorders and Phase Ib trials for moderate-to-severe knee osteoarthritis, and UBX1325, which is in Phase I trials for diabetic macular edema. Additionally, Unity is exploring treatments for various age-related conditions, including ophthalmologic, pulmonary, kidney, and liver diseases. Founded in 2009 and based in South San Francisco, California, Unity Biotechnology was formerly known as Forge, Inc. and rebranded in 2015.

IDEAYA Biosciences is an oncology-focused biotechnology company based in South San Francisco, California, dedicated to the discovery and development of targeted therapeutics for genetically defined patient populations. The company specializes in precision medicine using molecular diagnostics and synthetic lethality approaches to address cancer treatment. Its lead product candidate, IDE196, is a protein kinase C inhibitor currently undergoing Phase 1/2 clinical trials for cancers associated with GNAQ or GNA11 gene mutations. IDEAYA's preclinical pipeline includes programs targeting various mechanisms related to DNA damage and repair, such as MAT2A for tumors with MTAP deletions, Pol-theta for homologous recombination deficiency, and PARG for BRCA2 mutation context. The company collaborates with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase, while also engaging in partnerships for clinical trials with Pfizer and GlaxoSmithKline. Founded in 2015, IDEAYA aims to advance innovative therapies for enhancing immunotherapy responses and improving patient outcomes in oncology.

Medeor Therapeutics, Inc. is a biotechnology company based in San Mateo, California, focused on researching, developing, and commercializing personalized cellular immunotherapies. Founded in 2012, the company specializes in creating innovative treatments aimed at improving outcomes for kidney transplant recipients. Under the MDR-10X brand, Medeor Therapeutics develops cellular immunotherapy products that enhance organ transplant immune tolerance and advance immuno-oncology. These therapies are designed to better preserve or improve kidney function and reduce the risk of graft rejection compared to traditional immunosuppressive drugs.

XW Laboratories Inc. is a biopharmaceutical company based in Wuhan, China, specializing in the discovery and development of innovative treatments for neurological disorders. Established in 2014, the company has created three distinctive research and development platforms, including Prodrug and Functional Group Switch, which facilitate the rapid identification of new drug candidates while minimizing development costs and time. XW Laboratories aims to enhance patient compliance and reduce toxicity associated with existing medications. In addition to focusing on the domestic market, the company collaborates with international partners to extend its reach in foreign markets, positioning itself at the forefront of medicinal technology in the Asia-Pacific region.

LifeMine Therapeutics, Inc. is a biotechnology company focused on discovering new drug modalities from eukaryotic microbes, particularly fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, the company employs an integrated platform that combines genomics, artificial intelligence, and synthetic biology. This innovative Avatar-Rx platform utilizes high-throughput microbiology, data science, machine learning, genome engineering, and automation to explore the fungal biosphere for novel genetically encoded molecules with specific biological functions. By integrating chemoinformatic-assisted drug optimization and advanced chemical synthesis with biotransformation, LifeMine Therapeutics aims to advance a pipeline of new medicines into development.

Vivace Therapeutics, Inc. is a drug discovery and development company focused on creating cancer therapies that target the Hippo pathway, which plays a crucial role in tissue regeneration and organ development. Established in 2014 and located in the San Francisco Bay Area, Vivace Therapeutics employs an innovative approach to develop small molecule treatments aimed at improving patient outcomes in oncology. The company collaborates with leading academic institutions to advance research and develop therapies that can be used alone or in combination with existing treatments. With a commitment to enhancing cancer care, Vivace Therapeutics is dedicated to delivering novel solutions that can help patients combat cancer more effectively.

Ivenix, Inc. is a medical technology company based in North Andover, Massachusetts, that specializes in developing advanced intravenous (IV) infusion systems. Founded in 2001 and previously known as Fluidnet Corporation, Ivenix focuses on creating innovative solutions to improve infusion delivery in hospital settings. The company's flagship product is a next-generation infusion management system that employs pneumatic technology to accurately measure and control fluid flow, regardless of factors such as bag height, backpressure, patient movement, and fluid viscosity. This system not only simplifies the infusion process but also integrates with clinical information systems, enabling healthcare providers to manage patient infusion data effectively. By aiming to enhance the safety and efficiency of IV therapies, Ivenix is positioned to make a significant impact in the field of medical devices.

Forerunner Medical (Shanghai) Co., Ltd., established in 2009, specializes in the development and manufacturing of medical devices tailored for minimally invasive procedures. The company focuses on low-temperature plasma radio-frequency generators and electrodes, catering to sports medicine and tumor treatment. By leveraging domestic clinical data and technology from the United States, Forerunner Medical aims to meet both local and global healthcare needs. Their commitment to quality and safety is evident in their products, which are designed to offer enhanced performance, aesthetic appeal, and user convenience. With a strong emphasis on innovation and professional expertise, Forerunner Medical strives to provide superior medical technologies that improve surgical outcomes for doctors and patients alike.

TenNor Therapeutics is a clinical-stage product development company focused on addressing unmet medical needs in infectious diseases. The company utilizes a dual-acting drug discovery platform to develop innovative treatments for a range of conditions, including Helicobacter pylori infections, prosthetic joint infections, and multidrug-resistant Gram-negative infections. Additionally, TenNor is engaged in creating therapies for diseases associated with bacterial infections and dysbiosis, particularly targeting gastrointestinal tract infections and medical device-related infections. Through its multi-targeting approach, TenNor aims to bring new therapeutic options to patients suffering from various serious infectious diseases.

Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals for rare gastrointestinal conditions affecting infants. Established in 2003 and based in Ramat-Gan, Israel, the company is advancing clinical programs, including NTRA-2112, which aims to treat intestinal malabsorption in preterm infants by reducing enteral nutrition intolerance and improving growth metrics, as well as shortening hospital stays. Another significant product in development is NTRA-9620, designed for short bowel syndrome, which promotes bowel adaptation post-surgery and minimizes the need for parenteral nutrition. Nutrinia's offerings primarily consist of oral insulin formulations that facilitate gut adaptation and rehabilitation, thereby enhancing nutritional absorption in infants.

Avelas Biosciences is focused on enhancing cancer surgery through innovative intraoperative imaging technology. The company's proprietary platform employs activatable cell-penetrating peptides to facilitate real-time diagnosis of metastatic nodes during surgical procedures. This advancement allows oncologic surgeons to create a luminous map of the surgical site, which helps in identifying critical areas and improving surgical precision. By providing this real-time information, Avelas aims to reduce the likelihood of repeat surgeries and ultimately improve patient outcomes, setting a new standard of care in the field of oncology.

CStone Pharmaceuticals is a clinical-stage biotechnology company dedicated to developing and commercializing innovative immuno-oncology and molecularly targeted drugs aimed at addressing significant unmet medical needs in cancer treatment. Founded in 2015 and headquartered in Shanghai, China, the company has established a robust product pipeline that includes several late-stage clinical candidates, such as CS1001, a monoclonal antibody targeting programmed death ligand 1, and CS1003, which targets programmed death receptor. Other notable products include ivosidenib, avapritinib, and pralsetinib, along with a variety of additional investigational drugs for solid tumors and other cancer indications. CStone engages in strategic collaborations, including a licensing agreement with Numab Therapeutics for a tri-specific antibody and a clinical partnership with Bayer HealthCare to assess the efficacy of CS1001 in combination therapies. The company aims to enhance treatment options for cancer patients both in China and globally through its dedicated research and development efforts.

IDEAYA Biosciences is an oncology-focused biotechnology company based in South San Francisco, California, dedicated to the discovery and development of targeted therapeutics for genetically defined patient populations. The company specializes in precision medicine using molecular diagnostics and synthetic lethality approaches to address cancer treatment. Its lead product candidate, IDE196, is a protein kinase C inhibitor currently undergoing Phase 1/2 clinical trials for cancers associated with GNAQ or GNA11 gene mutations. IDEAYA's preclinical pipeline includes programs targeting various mechanisms related to DNA damage and repair, such as MAT2A for tumors with MTAP deletions, Pol-theta for homologous recombination deficiency, and PARG for BRCA2 mutation context. The company collaborates with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase, while also engaging in partnerships for clinical trials with Pfizer and GlaxoSmithKline. Founded in 2015, IDEAYA aims to advance innovative therapies for enhancing immunotherapy responses and improving patient outcomes in oncology.

Hua Medicine, established in 2009, is a Shanghai-based clinical-stage drug development company. It specializes in therapies for diabetes and central nervous system (CNS) disorders in China. The company's primary focus is Dorzagliatin, an oral drug for Type 2 diabetes, which is in Phase 3 clinical trials, both as a standalone treatment and in combination with metformin. Additionally, Hua Medicine is developing Dorzagliatin in combination with other drugs and mGLUR5 for Parkinson's disease levodopa-induced dyskinesia, both in pre-clinical stages. The company's mission is to address unmet medical needs in China through innovative drug development.

Adagene is a clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology antibodies targeting novel epitopes for cancer treatment. Utilizing its proprietary Smart Antibody Technology, Adagene aims to enhance the success rates of therapeutic antibodies while significantly accelerating the time to market and lowering development costs. The company is dedicated to the research, development, and production of monoclonal antibody drugs, with a pipeline that emphasizes creating therapeutic candidates characterized by functional epitopes and cross-reactivity across species. By transforming the discovery and development processes in the field of antibody-based cancer immunotherapies, Adagene is positioned to make a substantial impact on cancer treatment.

Forerunner Medical (Shanghai) Co., Ltd., established in 2009, specializes in the development and manufacturing of medical devices tailored for minimally invasive procedures. The company focuses on low-temperature plasma radio-frequency generators and electrodes, catering to sports medicine and tumor treatment. By leveraging domestic clinical data and technology from the United States, Forerunner Medical aims to meet both local and global healthcare needs. Their commitment to quality and safety is evident in their products, which are designed to offer enhanced performance, aesthetic appeal, and user convenience. With a strong emphasis on innovation and professional expertise, Forerunner Medical strives to provide superior medical technologies that improve surgical outcomes for doctors and patients alike.

Twist Bioscience Corporation is a synthetic biology company that specializes in the manufacture and sale of synthetic DNA-based products. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes a proprietary semiconductor-based DNA synthesis platform that writes DNA on silicon chips, allowing for the rapid and cost-effective production of high-quality synthetic DNA. Twist Bioscience's offerings include synthetic genes, tools for sample preparation, antibody libraries for drug discovery, and DNA as a medium for digital data storage. The company serves various sectors, including healthcare, agriculture, and industrial chemicals, supporting customers in their efforts to enhance lives and promote sustainability. Through its innovative platform, Twist Bioscience aims to overcome traditional inefficiencies in DNA synthesis, enabling researchers to accelerate their projects.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

Refuge Biotechnologies, Inc. is a Menlo Park, California-based company focused on developing cancer immunotherapies through the application of synthetic biology and gene-editing technology, specifically CRISPR-dCas. Founded in 2015, Refuge aims to enhance cell therapies by creating innovative treatments that can sense their environment and modulate multiple genes simultaneously. This approach allows for more potent and targeted cancer therapies, moving beyond traditional single-target treatments. The company's research and development efforts are centered on advancing both cancer diagnostics and immunotherapies to improve patient outcomes in cancer care.

AltheaDx, Inc. is a molecular diagnostics company based in San Diego, California, specializing in pharmacogenetics. The company employs an algorithm-based bioinformatics platform alongside a portfolio of pharmacogenomic product tests to aid healthcare providers in determining the most effective medications and appropriate dosing for patients based on their genetic profiles and existing treatment plans. Its IDgenetix test facilitates personalized treatment strategies for common health issues such as cardiovascular diseases, neuropsychiatric disorders, and pain management. Additionally, AltheaDx provides comprehensive research and development services, focusing on molecular biomarker discovery, assay development, and clinical trial support for pharmaceutical and biotech companies. The company serves a diverse clientele, including long-term care facilities, managed care organizations, and individual healthcare providers, thereby contributing to improved patient outcomes through tailored therapeutic decisions.

Lumo Bodytech Inc. specializes in developing technology that utilizes smart sensors and software to enhance human biomechanics and performance through real-time body movement tracking. The company's product lineup includes the Lumo Lift, a posture coach and activity tracker, and Lumo Run, a sensor that analyzes and improves running form. Additionally, the Lumo MotionScience platform offers feedback on human movement to aid users in optimizing their physical activities. Lumo Bodytech sells its products through various channels, including its own online store, other online retailers, international distribution partners, and physical retail locations. Founded in 2011 by Stanford entrepreneurs Monisha Perkash, Dr. Charles Wang, and Andrew Chang, the company was initially named Zero2one Inc. and rebranded in June 2014. Lumo Bodytech is headquartered in Mountain View, California, and is supported by several prominent investors.

23andMe, Inc. is a consumer genetics and research company headquartered in Sunnyvale, California, founded in 2006. It specializes in providing direct-to-consumer personal genome services through home-based saliva collection kits. The company offers a range of services, including Health + Ancestry, which provides insights into ancestry, traits, and health, and Ancestry + Traits, which details ancestry breakdown and various trait reports. 23andMe aims to help individuals understand their genetic makeup, enabling users to explore their ancestry, genealogy, and inherited traits. Additionally, the company markets its services to researchers and scientists, offering categorized and searchable genetic data. With a focus on consumer and research services, 23andMe is positioned within the rapidly growing biotech and healthcare sectors, contributing to the understanding of genetics and its implications for health.

Tunitas Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, focused on developing innovative protein therapeutics for individuals suffering from allergies. Founded in 2007, the company has created Epsi-gam, a genetically engineered bifunctional human fusion protein that combines elements of human IgE and IgG1, alongside allergen vaccines. Tunitas aims to provide targeted treatment options that can significantly alter the disease course for allergy sufferers, enabling them to receive therapies in their allergist’s office. The company's approach involves generating fusion proteins that inhibit key pathways in allergic cells, addressing the underlying mechanisms of IgE-mediated diseases such as asthma and severe food allergies.

Ivenix, Inc. is a medical technology company based in North Andover, Massachusetts, that specializes in developing advanced intravenous (IV) infusion systems. Founded in 2001 and previously known as Fluidnet Corporation, Ivenix focuses on creating innovative solutions to improve infusion delivery in hospital settings. The company's flagship product is a next-generation infusion management system that employs pneumatic technology to accurately measure and control fluid flow, regardless of factors such as bag height, backpressure, patient movement, and fluid viscosity. This system not only simplifies the infusion process but also integrates with clinical information systems, enabling healthcare providers to manage patient infusion data effectively. By aiming to enhance the safety and efficiency of IV therapies, Ivenix is positioned to make a significant impact in the field of medical devices.

Hua Medicine, established in 2009, is a Shanghai-based clinical-stage drug development company. It specializes in therapies for diabetes and central nervous system (CNS) disorders in China. The company's primary focus is Dorzagliatin, an oral drug for Type 2 diabetes, which is in Phase 3 clinical trials, both as a standalone treatment and in combination with metformin. Additionally, Hua Medicine is developing Dorzagliatin in combination with other drugs and mGLUR5 for Parkinson's disease levodopa-induced dyskinesia, both in pre-clinical stages. The company's mission is to address unmet medical needs in China through innovative drug development.

Vivace Therapeutics, Inc. is a drug discovery and development company focused on creating cancer therapies that target the Hippo pathway, which plays a crucial role in tissue regeneration and organ development. Established in 2014 and located in the San Francisco Bay Area, Vivace Therapeutics employs an innovative approach to develop small molecule treatments aimed at improving patient outcomes in oncology. The company collaborates with leading academic institutions to advance research and develop therapies that can be used alone or in combination with existing treatments. With a commitment to enhancing cancer care, Vivace Therapeutics is dedicated to delivering novel solutions that can help patients combat cancer more effectively.

Unity Biotechnology is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span by addressing diseases associated with aging. The company specializes in clearing senescent cells through the creation of senolytic medicines, which target vulnerabilities specific to these cells while preserving normal ones. Its lead drug candidates include UBX0101, currently undergoing Phase II trials for musculoskeletal disorders and Phase Ib trials for moderate-to-severe knee osteoarthritis, and UBX1325, which is in Phase I trials for diabetic macular edema. Additionally, Unity is exploring treatments for various age-related conditions, including ophthalmologic, pulmonary, kidney, and liver diseases. Founded in 2009 and based in South San Francisco, California, Unity Biotechnology was formerly known as Forge, Inc. and rebranded in 2015.

Adagene is a clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology antibodies targeting novel epitopes for cancer treatment. Utilizing its proprietary Smart Antibody Technology, Adagene aims to enhance the success rates of therapeutic antibodies while significantly accelerating the time to market and lowering development costs. The company is dedicated to the research, development, and production of monoclonal antibody drugs, with a pipeline that emphasizes creating therapeutic candidates characterized by functional epitopes and cross-reactivity across species. By transforming the discovery and development processes in the field of antibody-based cancer immunotherapies, Adagene is positioned to make a substantial impact on cancer treatment.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

Avelas Biosciences is focused on enhancing cancer surgery through innovative intraoperative imaging technology. The company's proprietary platform employs activatable cell-penetrating peptides to facilitate real-time diagnosis of metastatic nodes during surgical procedures. This advancement allows oncologic surgeons to create a luminous map of the surgical site, which helps in identifying critical areas and improving surgical precision. By providing this real-time information, Avelas aims to reduce the likelihood of repeat surgeries and ultimately improve patient outcomes, setting a new standard of care in the field of oncology.

IMPACT Therapeutics, Inc. is a biotechnology company based in Shanghai, China, focused on discovering, developing, and commercializing innovative therapeutics for cancer and other life-threatening diseases. Founded in 2009, the company is dedicated to creating targeted anti-cancer treatments that leverage the concept of synthetic lethality. Its research and development efforts include a variety of novel drug projects, such as PARP inhibitors, Wee1 inhibitors, and agents targeting the Hedgehog pathway, among other DNA damage response (DDR) agents. Through its commitment to advancing targeted therapies, IMPACT Therapeutics aims to provide patients with new, effective treatment options for challenging medical conditions.

Hua Medicine, established in 2009, is a Shanghai-based clinical-stage drug development company. It specializes in therapies for diabetes and central nervous system (CNS) disorders in China. The company's primary focus is Dorzagliatin, an oral drug for Type 2 diabetes, which is in Phase 3 clinical trials, both as a standalone treatment and in combination with metformin. Additionally, Hua Medicine is developing Dorzagliatin in combination with other drugs and mGLUR5 for Parkinson's disease levodopa-induced dyskinesia, both in pre-clinical stages. The company's mission is to address unmet medical needs in China through innovative drug development.